An Open-Label Study of Azetukalner in Major Depressive Disorder

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions
Major Depressive Disorder
Interventions
DRUG

Azetukalner

Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.

Trial Locations (24)

10314

Richmond Behavioral Associates, Staten Island

11229

Integrative Clinical Trials, Llc, Brooklyn

28211

New Hope Clinical Research, Charlotte

30030

Cenexel Iresearch - Atlanta, Decatur

30060

Psych Atlanta, Pc, Marietta

32256

Clinical Neuroscience Solutions Inc. - Jacksonville, Jacksonville

32502

Panhandle Research and Medical Clinic, Pensacola

32807

Combined Research Orlando Phase I-Iv, Orlando

33016

Neoclinical Research, Hialeah

33146

Pharmasouth Research, Coral Gables

33162

Harmony Clinical Research Inc, North Miami Beach

33777

Accel Research Sites - St. Petersburg-Largo, Largo

38119

Clinical Neuroscience Solutions, Inc., Memphis

60634

Chicago Research Center Inc., Chicago

72211

Woodland International Research Group, Little Rock

72758

Woodland Research Northwest, Rogers

85012

Ima Clinical Research - Phoenix, Phoenix

89102

Ima Clinical Research - Las Vegas, Las Vegas

89119

Redbird Research, Las Vegas

90501

Cenexel Cns - Torrance, Torrance

92056

Excell Research Inc., Oceanside

92866

Atp Clinical Research, Orange

92868

Nrc Research Institute, Orange

98201

Core Clinical Research, Everett

All Listed Sponsors
lead

Xenon Pharmaceuticals Inc.

INDUSTRY